Literature DB >> 15793875

Apoptosis of human gastric cancer SGC-7901 cells induced by mitomycin combined with sulindac.

Li Ma1, Yong-Le Xie, Yi Yu, Qiu-Ning Zhang.   

Abstract

AIM: To investigate the effects of mitomycin (MMC) combined with sulindac on cell viability, apoptotic induction and expression of apoptosis-related gene Bcl-2 and cyclooxygenase-2 (COX-2) in gastric cancer SGC-7901 cells.
METHODS: Human gastric cancer SGC-7901 cells were divided into three treatment groups,namely sulindac treatment group, MMC treatment group and combined sulindac with MMC treatment group. After being treated with drugs, cell viability was examined by MTT assay. Flow cytometry was used to evaluate the cell cycle distribution and apoptotic rates. Morphology of the cells was observed under light microscope and interactive laser microscope. Expression of COX-2 and Bcl-2 was determined by immunocytochemical method.
RESULTS: After exposure for 12 h to three kinds of drugs, gastric cancer SGC-7901 cells presented some morphological features of apoptosis, including cell shrinkage, nuclear condensation, DNA fragmentation and formation of apoptotic bodies. Growth inhibition was more obvious in combined sulindac with MMC treatment group and sulindac treatment group than in MMC treatment group. The apoptotic rates in co-treated cells and MMC-treated cells 24 h after treatment were 12.0% and 7.2%, respectively. After exposure for 24 h to MMC, the expression of COX-2 and Bcl-2 protein was up-regulated, COX-2 levels were down-regulated but Bcl-2 gene expression was not changed significantly in combined treatment group.
CONCLUSION: MMC-induced apoptosis is reduced by up-regulating the expression of COX-2 and Bcl-2 genes. MMC combined with sulindac can suppress the growth of gastric cancer cells through induction of apoptosis mediated by down-regulation of apoptosis-related Bcl-2 and COX-2 gene.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15793875      PMCID: PMC4305885          DOI: 10.3748/wjg.v11.i12.1829

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  19 in total

1.  Cyclooxygenase-2 activity altered the cell-surface carbohydrate antigens on colon cancer cells and enhanced liver metastasis.

Authors:  Yoshimi Kakiuchi; Shingo Tsuji; Masahiko Tsujii; Hiroaki Murata; Naoki Kawai; Masakazu Yasumaru; Arata Kimura; Masato Komori; Takanobu Irie; Eiji Miyoshi; Yutaka Sasaki; Norio Hayashi; Sunao Kawano; Masatsugu Hori
Journal:  Cancer Res       Date:  2002-03-01       Impact factor: 12.701

2.  Selective inhibition of cyclooxygenase-2 enhances mitomycin-C-induced apoptosis.

Authors:  C T Hsueh; C F Chiu; D P Kelsen; G K Schwartz
Journal:  Cancer Chemother Pharmacol       Date:  2000       Impact factor: 3.333

3.  Expression of cyclooxygenase-2 in human gastric carcinoma.

Authors:  A Ristimäki; N Honkanen; H Jänkälä; P Sipponen; M Härkönen
Journal:  Cancer Res       Date:  1997-04-01       Impact factor: 12.701

4.  The MDR phenotype is associated with the expression of COX-2 and iNOS in a human hepatocellular carcinoma cell line.

Authors:  Ornella Fantappiè; Emanuela Masini; Iacopo Sardi; Laura Raimondi; Daniele Bani; Michela Solazzo; Alfredo Vannacci; Roberto Mazzanti
Journal:  Hepatology       Date:  2002-04       Impact factor: 17.425

5.  Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus.

Authors:  Navtej S Buttar; Kenneth K Wang; Olga Leontovich; Jay Y Westcott; Rodney J Pacifico; Marlys A Anderson; Krishnawatie K Krishnadath; Lori S Lutzke; Lawrence J Burgart
Journal:  Gastroenterology       Date:  2002-04       Impact factor: 22.682

6.  Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth.

Authors:  M Mann; H Sheng; J Shao; C S Williams; P I Pisacane; M X Sliwkowski; R N DuBois
Journal:  Gastroenterology       Date:  2001-06       Impact factor: 22.682

7.  The association between a mutated ras gene and cyclooxygenase-2 expression in human breast cancer cell lines.

Authors:  E M Gilhooly; D P Rose
Journal:  Int J Oncol       Date:  1999-08       Impact factor: 5.650

8.  Sulindac inhibits activation of the NF-kappaB pathway.

Authors:  Y Yamamoto; M J Yin; K M Lin; R B Gaynor
Journal:  J Biol Chem       Date:  1999-09-17       Impact factor: 5.157

9.  Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line.

Authors:  T Miyashita; J C Reed
Journal:  Blood       Date:  1993-01-01       Impact factor: 22.113

10.  NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells.

Authors:  X H Liu; S Yao; A Kirschenbaum; A C Levine
Journal:  Cancer Res       Date:  1998-10-01       Impact factor: 12.701

View more
  2 in total

1.  Sulindac induces apoptosis and inhibits tumor growth in vivo in head and neck squamous cell carcinoma.

Authors:  Mark A Scheper; Nikolaos G Nikitakis; Risa Chaisuparat; Silvia Montaner; John J Sauk
Journal:  Neoplasia       Date:  2007-03       Impact factor: 5.715

2.  Up-regulation of hypoxia inducible factor-1α by cobalt chloride correlates with proliferation and apoptosis in PC-2 cells.

Authors:  Zhi-Jun Dai; Jie Gao; Xiao-Bin Ma; Kun Yan; Xiao-Xu Liu; Hua-Feng Kang; Zong-Zheng Ji; Hai-Tao Guan; Xi-Jing Wang
Journal:  J Exp Clin Cancer Res       Date:  2012-03-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.